Prescribing overview
UpCard-CA1 manages pulmonary edema in stable dogs with congestive heart failure due to myxomatous mitral valve disease, with pimobendan, spironolactone and an ACE inhibitor. Conditional approval is not full effectiveness approval; extra-label use of this product is prohibited.
UpCard-CA1 manages pulmonary edema in stable dogs with congestive heart failure due to myxomatous mitral valve disease, with pimobendan, spironolactone and an ACE inhibitor. Conditional approval is not full effectiveness approval; extra-label use of this product is prohibited.
Key prescribing checks
- Confirm the indication, route, current weight, disease status and concurrent treatments before prescribing.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Dogs
FDA conditionally approved; use only as labeledManagement of MMVD-associated pulmonary edema with specified concurrent therapy
US conditionally approved UpCard-CA1 canine solution; indication and concurrent-treatment conditions apply.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Inhibits renal sodium/chloride reabsorption, increasing urine production.
Absorption, distribution, metabolism and elimination
Highly protein-bound; much of the administered drug is excreted unchanged in urine.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
UpCard-CA1
US conditionally approved UpCard-CA1 canine solution; indication and concurrent-treatment conditions apply.
Contraindications · when not to use
- Renal failure, anuria, severe dehydration, hypovolemia, hypotension, product hypersensitivity, or concurrent loop diuretics.
Precautions & monitoring
- Correct dehydration and electrolyte abnormalities first. This oral product is not indicated for emergency pulmonary-edema crises.
Selected product information; this is not a complete interaction or patient-specific prescribing assessment.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Excessive diuresis, thirst, electrolyte disturbances, renal impairment and gastrointestinal signs can occur.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
A verified veterinary dose has not been entered for this product. Human-label dosing must not be used as an animal regimen. Consult a current species-specific clinical source and the prescribing veterinarian.
No numeric regimen is supplied in this entry. The veterinarian must consult the exact current product label; this entry does not enable a dosing calculator.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This monograph summarizes selected interactions. The comparison tool applies a curated set of rules and is not comprehensive. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
Compare with other medications and check species →
UpCard-CA1
US conditionally approved UpCard-CA1 canine solution; indication and concurrent-treatment conditions apply.
- Review NSAIDs, nephrotoxic antibiotics, digoxin, corticosteroids, amphotericin B and salicylates.
Monitoring
Assess hydration, kidney values and electrolytes before treatment or adjustment, at 24 and 48 hours, then monthly until stable.
Client counseling
Keep water available and maintain the prescribed recheck plan. New breathing difficulty needs urgent assessment. Do not add furosemide or adjust the diuretic independently.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Store at or below 30°C and discard 90 days after opening.
Brands, formulations & ingredient identity
Active ingredients
Torsemide
Other searchable names: Torasemide · UpCard-CA1 · UpCard CA1
This reference is limited to the named product and presentation; matching ingredients do not establish interchangeability.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
UpCard-CA1
- Formulation
- Canine oral solution
- Label / product scope
- Dogs
US conditionally approved UpCard-CA1 canine solution; indication and concurrent-treatment conditions apply.
Product label / source ↗References & review status
Clinical reference updated October 27, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →